Vitamin D Supplementation and the Incidence of Cataract Surgery in Older Australian Adults.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

However, no randomized controlled trials have assessed the effect of vitamin D supplementation on the incidence of cataract.

Why It Was Studied

Proprietary or commercial disclosure may be found after the references.

Who Took Part

According to the abstract, 421,207 men were involved.

By PubMed's age tags, the people studied were older adults, both men and women.

The researchers invited 421 207 men and women 60 to 84 years of age to participate; including an additional 1896 volunteers, 40 824 expressed interest.

A total of 21 315 were randomized, and 1390 participants did not fulfil the eligibility criteria for this analysis (linked data available, no cataract within first 6 months), leaving 19 925 included.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The men were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some men received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

The median follow-up was 5 years.

What Was Measured

PubMed files the paper under topics including Incidence, Ultraviolet Rays, Australia, Vitamin D, Vitamins and Dietary Supplements.

Author keywords: Cataract, Randomized controlled trial and Vision loss.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 421,207 men.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Ophthalmology), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.